New Pharmaceutical Regulations In 2008
This article was originally published in PharmAsia News
New Pharmaceutical Regulations In 2008 Whether China's pharmaceutical industry will continue making gains depends on 2008's health reform plan and new regulations taking effect Jan. 1, such as those for drug GMP authentication standards and pollutant standards. Also coming into effect in the new year are laws for anti-monopoly and new corporate income taxes. Analysts see the revised taxation law, which standardizes tax rates at 25 percent for domestic and foreign-funded companies, as a significant milestone for local enterprises as they will be more competitive with multinational corporations. (Click here for more)
You may also be interested in...
Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.
Market Brief: Tissue-Engineered Wound Care Market Expected To Reach $1.9BN By 2024 Amid Rising Chronic Disease
The skin replacement market is led by three key players who have all been impacted by COVID-19, but the sector may see a quicker rebound than others as treatments cannot be deferred for a long time.
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.